Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

U. Callaghan, Michael; Négrier, Claude; Paz‐Priel, Ido; Chang, Tiffany; Chebon, Sammy; Lehle, Michaela; Mahlangu, Johnny; Young, Guy; Kruse‐Jarres, Rebecca; Elisa Mancuso, Maria; Niggli, Markus; Howard, Monet; Selak Bienz, Nives; Shima, Midori; Jiménez‐Yuste, Víctor; Schmitt, Christophe; Asikanius, Elina; G. Levy, Gallia; W. Pipe, Steven; Oldenburg, Johannes

doi:10.1182/blood.2020009217

Public

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

Published in Blood • Dec 19, 2020

Authors:

Michael U. Callaghan

Claude Négrier

Ido Paz‐Priel

Abstract

Prophylaxis with emicizumab, a subcutaneously administered bispecific humanized monoclonal antibody, promotes effective hemostasis in persons with hemophilia A (PwHAs). The primary efficacy, safety, and pharmacokinetics of emicizumab were reported previously, but long-term data were limited. Here, d...

Subject

Medicine

Adverse effect

Confidence interval

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!